Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xingnaojing plus Naoxueshu for acute intracerebral hemorrhage
ChiCTR1900026422Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2019
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Xingnaojing and naoxueshu in intracerebral hemorrhage (ICH) (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: modified Rankin Scale. Planned start Jan 2019; status: not yet recruiting.
02
Drugs
Xingnaojingnaoxueshu
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR1900026422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026422.